{"id":"https://openalex.org/W4379282945","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3023","title":"Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.","display_name":"Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379282945","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3023"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2023.41.16_suppl.3023","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3023","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.3023","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069337573","display_name":"Kathleen N. Moore","orcid":"https://orcid.org/0000-0002-5803-0718","observed_orcids":["https://orcid.org/0000-0002-5803-0718"]},"institutions":[{"id":"https://openalex.org/I4390039380","display_name":"OU Health Stephenson Cancer Center","ror":"https://ror.org/02bmcqd02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039271","https://openalex.org/I4390039380"]},{"id":"https://openalex.org/I8692664","display_name":"University of Oklahoma","ror":"https://ror.org/02aqsxs83","country_code":"US","type":"education","lineage":["https://openalex.org/I8692664"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen N. Moore","raw_affiliation_strings":["Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK","institution_ids":["https://openalex.org/I4390039380","https://openalex.org/I8692664"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004158484","display_name":"Dhanusha Sabanathan","orcid":"https://orcid.org/0000-0001-6654-3452","observed_orcids":["https://orcid.org/0000-0001-6654-3452"]},"institutions":[{"id":"https://openalex.org/I99043593","display_name":"Macquarie University","ror":"https://ror.org/01sf06y89","country_code":"AU","type":"education","lineage":["https://openalex.org/I99043593"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Dhanusha Sabanathan","raw_affiliation_strings":["Macquarie University Cancer Institute, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Macquarie University Cancer Institute, Sydney, Australia","institution_ids":["https://openalex.org/I99043593"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100783340","display_name":"Yiqun Du","orcid":"https://orcid.org/0000-0002-2870-6510","observed_orcids":["https://orcid.org/0000-0002-2870-6510"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yiqun Du","raw_affiliation_strings":["Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113390595","display_name":"Huaxin Duan","orcid":"https://orcid.org/0000-0001-9596-5013","observed_orcids":["https://orcid.org/0000-0001-9596-5013"]},"institutions":[{"id":"https://openalex.org/I4210147389","display_name":"Hunan Provincial People's Hospital","ror":"https://ror.org/03wwr4r78","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210147389"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Huaxin Duan","raw_affiliation_strings":["Hunan Provincial People's Hospital, Changsha, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hunan Provincial People's Hospital, Changsha, China","institution_ids":["https://openalex.org/I4210147389"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100652986","display_name":"Xiumin Li","orcid":"https://orcid.org/0000-0002-0151-9176","observed_orcids":["https://orcid.org/0000-0002-0151-9176"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiumin Li","raw_affiliation_strings":["Linyi Cancer Hospital, Shandong, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Linyi Cancer Hospital, Shandong, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009177260","display_name":"Feng Wang","orcid":"https://orcid.org/0009-0002-3781-2806","observed_orcids":["https://orcid.org/0009-0002-3781-2806"]},"institutions":[{"id":"https://openalex.org/I4210156804","display_name":"First Affiliated Hospital of Zhengzhou University","ror":"https://ror.org/056swr059","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210156804"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Feng Wang","raw_affiliation_strings":["The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China","institution_ids":["https://openalex.org/I4210156804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051149549","display_name":"Omkar Subhash Marathe","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Omkar Marathe","raw_affiliation_strings":["The Oncology Institute, Lakewood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Oncology Institute, Lakewood, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058609108","display_name":"Hua Yang","orcid":"https://orcid.org/0000-0001-9074-9477","observed_orcids":["https://orcid.org/0000-0001-9074-9477"]},"institutions":[{"id":"https://openalex.org/I4210140680","display_name":"Affiliated Hospital of Hebei University","ror":"https://ror.org/049vsq398","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210140680"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Hua Yang","raw_affiliation_strings":["Affiliated Hospital of Hebei University, Hebei, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affiliated Hospital of Hebei University, Hebei, China","institution_ids":["https://openalex.org/I4210140680"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074877517","display_name":"Vicky Makker","orcid":"https://orcid.org/0000-0001-9793-7614","observed_orcids":["https://orcid.org/0000-0001-9793-7614"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vicky Makker","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053081492","display_name":"Whitfield B. Growdon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039310","display_name":"NYU Langone\u2019s Laura and Isaac Perlmutter Cancer Center","ror":"https://ror.org/00sa8g751","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933","https://openalex.org/I4390039310"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Whitfield Growdon","raw_affiliation_strings":["Perlmutter Cancer Center at NYU Langone Health, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Perlmutter Cancer Center at NYU Langone Health, New York, NY","institution_ids":["https://openalex.org/I4390039310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053835464","display_name":"Jermaine Ian George Coward","orcid":"https://orcid.org/0000-0002-2309-9379","observed_orcids":["https://orcid.org/0000-0002-2309-9379"]},"institutions":[{"id":"https://openalex.org/I4210167184","display_name":"Icon (Australia)","ror":"https://ror.org/05nh0hr31","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210167184"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jim Coward","raw_affiliation_strings":["ICON Cancer Centre, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICON Cancer Centre, Brisbane, Australia","institution_ids":["https://openalex.org/I4210167184"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058548650","display_name":"Peng Zhao","orcid":"https://orcid.org/0000-0002-5479-899X","observed_orcids":["https://orcid.org/0000-0002-5479-899X"]},"institutions":[{"id":"https://openalex.org/I4210166576","display_name":"First Affiliated Hospital Zhejiang University","ror":"https://ror.org/05m1p5x56","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210166576"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Peng Zhao","raw_affiliation_strings":["The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China","institution_ids":["https://openalex.org/I4210166576"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Liming Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Liming Liu","raw_affiliation_strings":["Duality Biologics, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duality Biologics, Philadelphia, PA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091215198","display_name":"Rong Shi","orcid":"https://orcid.org/0009-0005-8195-7190","observed_orcids":["https://orcid.org/0009-0005-8195-7190"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rong Shi","raw_affiliation_strings":["Duality Biologics, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duality Biologics, Princeton","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070156033","display_name":"Shengxue Liu","orcid":"https://orcid.org/0000-0003-1273-9438","observed_orcids":["https://orcid.org/0000-0003-1273-9438"]},"institutions":[{"id":"https://openalex.org/I4405267171","display_name":"Duality Biotherapeutics, Inc. (China)","ror":"https://ror.org/01gh8xc13","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267171"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Shengxue Liu","raw_affiliation_strings":["Duality Biologics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duality Biologics, Shanghai, China","institution_ids":["https://openalex.org/I4405267171"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Wei Gu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267171","display_name":"Duality Biotherapeutics, Inc. (China)","ror":"https://ror.org/01gh8xc13","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267171"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wei Gu","raw_affiliation_strings":["Duality Biologics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duality Biologics, Shanghai, China","institution_ids":["https://openalex.org/I4405267171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104124554","display_name":"Yang Qiu","orcid":"https://orcid.org/0009-0001-7737-2668","observed_orcids":["https://orcid.org/0009-0001-7737-2668"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yang Qiu","raw_affiliation_strings":["Duality Biologics, Basking Ridge, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duality Biologics, Basking Ridge, NJ","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Zhongyuan Zhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267171","display_name":"Duality Biotherapeutics, Inc. (China)","ror":"https://ror.org/01gh8xc13","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267171"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhongyuan Zhu","raw_affiliation_strings":["Duality Biologics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duality Biologics, Shanghai, China","institution_ids":["https://openalex.org/I4405267171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100409969","display_name":"Jian Zhang","orcid":"https://orcid.org/0000-0002-5093-4325","observed_orcids":["https://orcid.org/0000-0002-5093-4325"]},"institutions":[{"id":"https://openalex.org/I133868755","display_name":"Shanghai Medical College of Fudan University","ror":"https://ror.org/01zntxs11","country_code":"CN","type":"education","lineage":["https://openalex.org/I133868755","https://openalex.org/I24943067"]},{"id":"https://openalex.org/I24943067","display_name":"Fudan University","ror":"https://ror.org/013q1eq08","country_code":"CN","type":"education","lineage":["https://openalex.org/I24943067"]},{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jian Zhang","raw_affiliation_strings":["Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China","institution_ids":["https://openalex.org/I133868755","https://openalex.org/I24943067","https://openalex.org/I4210093194"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika P. Hamilton","raw_affiliation_strings":["Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":16,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"16_suppl","first_page":"3023","last_page":"3023"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9282000064849854,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9282000064849854,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.021800000220537186,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.01940000057220459,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9639999866485596},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.6660000085830688},{"id":"https://openalex.org/keywords/anti-her2-monoclonal-antibody","display_name":"anti-HER2 monoclonal antibody","score":0.8100000023841858},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.8840000033378601},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.6600000262260437},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7490000128746033},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9070000052452087},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7820000052452087},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7580000162124634},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8619999885559082},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.5410000085830688},{"id":"https://openalex.org/keywords/first-in-human","display_name":"first-in-human","score":0.5210000276565552}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8890084028244019},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.735379695892334},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7330362200737},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6700552701950073},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6301572322845459},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6019836664199829},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.551731288433075},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5364758372306824},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.48226791620254517},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.46249154210090637},{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.4579415023326874},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4374883472919464},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42320823669433594},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37893569469451904},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.2621142864227295},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.24043932557106018},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.1753806471824646},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.142488032579422}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2023.41.16_suppl.3023","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.3023","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.3023","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393987801","https://openalex.org/W4365512358","https://openalex.org/W4410814481","https://openalex.org/W7129605709","https://openalex.org/W4393988222","https://openalex.org/W4402471571","https://openalex.org/W4415942575","https://openalex.org/W4394883394","https://openalex.org/W4307907164","https://openalex.org/W2889795097"],"abstract_inverted_index":{"3023":[0],"Background:":[1],"DB-1303":[2,76,118,257,271,294,398],"is":[3,39,273,431],"an":[4],"antibody-drug":[5],"conjugate":[6],"(ADC)":[7],"consisting":[8],"of":[9,111,135,141,150,155,256,270,284,293,298,306],"a":[10,26,32,40,133],"humanized":[11],"anti-HER2":[12,145],"IgG1":[13],"monoclonal":[14],"antibody,":[15],"covalently":[16],"linked":[17],"to":[18,234,265],"proprietary":[19],"DNA":[20],"topoisomerase":[21],"I":[22],"inhibitor":[23],"(P1003)":[24],"via":[25],"maleimide":[27],"tetrapeptide-based":[28],"cleavable":[29],"linker,":[30],"with":[31,50,57,260,339,382,402,411,418],"high":[33],"drug-to-antibody":[34],"ratio":[35],"(~8).":[36],"Methods:":[37],"This":[38],"global":[41],"first-in-human,":[42],"dose-escalation":[43],"and":[44,74,98,128,131,162,173,184,211,223,254,365,385,393,421],"-expansion":[45],"study":[46],"in":[47,148,180,240,301,407,416,427,433],"patients":[48],"(pts)":[49],"advanced/metastatic":[51,412],"solid":[52,413],"tumors.":[53],"Pts":[54],"(ECOG":[55],"0-1)":[56],"HER2":[58,345],"\u2013":[59],"(high":[60],"or":[61,64,90,231],"low)":[62],"expressing":[63],"mutant":[65],"cancers":[66],"who":[67],"failed":[68],"previously":[69],"systemic":[70,302],"therapies":[71],"were":[72,83,193,390],"recruited":[73],"received":[75,117,132],"intravenously":[77],"Q3W":[78],"as":[79,424,426],"monotherapy.":[80],"The":[81,152,249,268,282],"objectives":[82],"safety,":[84],"tolerability,":[85],"maximum":[86],"tolerated":[87,401],"dose":[88,94,121,280],"(MTD)":[89],"recommended":[91],"phase":[92],"2":[93,241,350],"(PR2D),":[95],"pharmacokinetics":[96],"(PK),":[97],"preliminary":[99,404],"antitumor":[100,405],"activity.":[101],"Here":[102],"we":[103],"report":[104],"the":[105,189,299,373,375,388,439],"results":[106],"from":[107,263],"dose-escalation.":[108],"Results:":[109],"As":[110],"Jan":[112],"13,":[113],"2023,":[114],"85":[115],"pts":[116,164,182,186,218,242,308,318,338,381,410,417,436],"at":[119,311,438],"6":[120],"levels":[122],"(2.2,":[123],"4.4,":[124],"6.0,":[125],"7.0,":[126],"8.0,":[127],"10.0":[129,266],"mg/kg)":[130],"median":[134,153],"7":[136],"(range,":[137,159],"1-27)":[138],"prior":[139],"lines":[140],"therapy,":[142],"including":[143,336],"previous":[144],"ADC":[146,258,272,300],"therapy":[147],"32.9%":[149],"pts.":[151],"duration":[154],"treatment":[156],"was":[157,228,288,377,399],"63.0":[158],"21-211)":[160],"days,":[161],"68":[163],"(80.0%)":[165],"remained":[166],"on":[167],"treatment.":[168],"Treatment-emergent":[169],"adverse":[170],"events":[171],"(TEAEs)":[172],"\u2265":[174,197,202,209,215,247],"grade":[175],"(G)":[176],"3":[177],"TEAEs":[178,192,232],"occurred":[179,239],"74":[181],"(87.1%)":[183],"18":[185],"(21.2%),":[187],"respectively;":[188],"most":[190],"common":[191],"nausea":[194],"(51.8%,":[195],"3.5%":[196,208],"G3),":[198,203,210],"vomiting":[199],"(43.5%,":[200],"1.2%":[201],"platelet":[204],"count":[205],"decreased":[206],"(35.3%,":[207],"anemia":[212],"(29.4%,":[213],"5.9%":[214],"G3).":[216],"Few":[217],"experienced":[219],"neutropenia":[220],"(10":[221],"[11.8%])":[222],"alopecia":[224],"(3":[225],"[3.5%]).":[226],"There":[227],"no":[229],"DLT":[230],"leading":[233],"death.":[235],"Interstitial":[236],"lung":[237],"disease":[238],"(2.4%,":[243],"G1),":[244],"without":[245],"any":[246],"G2.":[248],"exposure":[250,283],"parameters":[251],"(C":[252],"max":[253],"AUC)":[255],"increased":[259],"ascending":[261],"doses":[262],"2.2":[264],"mg/kg.":[267],"half-life":[269],"approximately":[274],"6-7":[275],"days":[276],"for":[277,380],"6.0-8.0":[278],"mg/kg":[279],"cohorts.":[281],"serum":[285],"release":[286],"payload":[287],"magnitudes":[289],"lower":[290],"than":[291],"that":[292],"ADC,":[295],"demonstrating":[296],"stability":[297],"circulation.":[303],"A":[304],"total":[305],"52":[307],"had":[309,321],"undergone":[310],"least":[312],"one":[313],"post-baseline":[314],"tumor":[315,324,435],"scan.":[316],"Twenty-three":[317],"(44.2%,":[319],"23/52)":[320],"objective":[322],"partial":[323],"response":[325],"per":[326],"RECIST":[327],"1.1:":[328],"Thirteen":[329],"HER2+":[330,383,419],"breast":[331],"cancer":[332,352,362,368],"(BC)":[333],"(50.0%,":[334,363,369],"13/26,":[335],"5":[337,344],"brain":[340,422],"metastases":[341],"[55.6%,":[342],"5/9]),":[343],"low":[346],"BC":[347,384,420],"(38.5%,":[348],"5/13),":[349],"colorectal":[351],"(66.7%,":[353],"2/3),":[354],"1":[355,360,366],"endometrial":[356],"carcinoma":[357],"(33.3%,":[358],"1/3),":[359],"esophageal":[361],"1/2),":[364],"ovarian":[367],"1/2).":[370],"Among":[371],"all":[372],"pts,":[374],"DCR":[376],"88.5%":[378],"(46/52);":[379],"HER2-low":[386,428],"BC,":[387],"DCRs":[389],"96.2%":[391],"(25/26)":[392],"84.6%":[394],"(11/13),":[395],"respectively.":[396],"Conclusions:":[397],"well":[400,425],"encouraging":[403],"activity":[406],"heavily":[408],"pretreated":[409],"tumors,":[414],"especially":[415],"metastasis":[423],"BC.":[429],"Expansion":[430],"ongoing":[432],"selected":[434],"treated":[437],"RP2D.":[440],"Clinical":[441],"trial":[442],"information:":[443],"NCT05150691":[444],".":[445]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2023-06-05T00:00:00"}